Clincosm LogoSign in Get a demo

Testing the Contribution of Orbitofrontal Cortex Networks to Reward Identity Learning

Sponsor
Northwestern University (Other)
Overall Status
Completed
CT.gov ID
NCT04926961
Collaborator
(none)
42
Enrollment
1
Location
2
Arms
4.6
Actual Duration (Months)
9.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This research study examines the contribution of orbitofrontal cortex (OFC) networks to learning reward identity expectations.

Condition or Disease Intervention/Treatment Phase
  • Device: Sham transcranial magnetic stimulation (TMS)
  • Device: Real transcranial magnetic stimulation (TMS)
 N/A

Detailed Description

This study is designed to examine the contribution of OFC networks to reward identity learning. It will use network-targeted TMS to test whether OFC is necessary for reward identity learning. Healthy human subjects will perform a three-reward reversal learning task after either TMS or sham stimulation while fMRI data are acquired. This is a randomized, within-subject, cross-over study.

Study Design

Study Type:
Interventional
Actual Enrollment :
42 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Participants receive both sham TMS stimulation and real TMS stimulation in different sessions.Participants receive both sham TMS stimulation and real TMS stimulation in different sessions.
Masking:
Single (Participant)
Primary Purpose:
Basic Science
Official Title:
Testing the Contribution of Orbitofrontal Cortex Networks to Reward Identity Learning
Actual Study Start Date :
Jun 16, 2021
Actual Primary Completion Date :
Nov 3, 2021
Actual Study Completion Date :
Nov 3, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Sham stimulation first, then real stimulation

Participants will first be delivered sham TMS stimulation. Then on a separate day, participants will be delivered real TMS stimulation.

Device: Sham transcranial magnetic stimulation (TMS)
Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.

Device: Real transcranial magnetic stimulation (TMS)
Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil.
Experimental: Real stimulation first, then sham stimulation

Participants will first be delivered real TMS stimulation. Then on a separate day, participants will be delivered sham TMS stimulation.

Device: Sham transcranial magnetic stimulation (TMS)
Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.

Device: Real transcranial magnetic stimulation (TMS)
Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil.

Outcome Measures

Primary Outcome Measures

  1. Percentage of correct outcome predictions [1 hour]

    Percentage of correct outcome predictions in response to predictive cues during the reversal learning task.

  2. Blood oxygen level-dependent (BOLD) responses [1 hour]

    Blood oxygen level-dependent (BOLD) responses measured using functional magnetic resonance imaging (fMRI) during the reversal learning task.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • Age between 18 and 50 years old

  • Right-handed

  • Fluent English speakers

Exclusion Criteria:

  • History of significant neurological conditions (e.g., epilepsy, dementia, multiple sclerosis, brain tumors, etc.)

  • History of major psychiatric conditions (e.g., general anxiety disorder, depression, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder, alcoholism, etc.)

  • Significant medical illnesses (e.g., cancer, meningitis, chronic obstructive pulmonary disease, cardiovascular disease, etc.)

  • Significant cerebrovascular risk factors (e.g., hypertension, diabetes, elevated cholesterol, etc.)

  • Current use of psychoactive medications (e.g., barbiturates, benzodiazepines, chloral hydrate, haloperidol, lithium, carbamazepine, phenytoin, citalopram, escitalopram, fluoxetine, diazepam, etc.)

  • Smell or taste dysfunction

  • History of significant allergies requiring hospitalization for treatment

  • History of severe asthma requiring hospitalization for treatment

  • Habitual smoking

  • Magnetic implants (e.g., shunts or stents, aneurysm clips, surgical clips, cochlear implants, metal bone/joint pins, plates and screws, eyelid spring or wires, etc.)

  • Electronic devices (e.g., implanted cardiac defibrillator, cardiac pacemaker, deep brain/spinal cord or nerve stimulator, internal electrodes/wires, medication infusion devices, etc.)

  • History of metal working without proper eye protection, or injury with metal shrapnel or metal slivers

  • Claustrophobia

  • Pregnancy

  • Predisposition to seizures (e.g., personal history of seizures, family history of seizures epilepsy, pregnancy, alcoholism, etc.)

  • Use of medications that increase the likelihood of seizures (e.g., bupropion, citalopram, duloxetine, ketamine, gamma-hydroxybutyrate, etc.)

  • History of surgical procedures performed on the brain or spinal cord

  • History of severe head trauma followed by loss of consciousness

  • History of fainting spells or syncope

  • Hearing problems or tinnitus

Contacts and Locations

Locations

Site City State Country Postal Code
1 Northwestern University Chicago Illinois United States 60611

Sponsors and Collaborators

  • Northwestern University

Investigators

  • Principal Investigator: Christina Zelano, PhD, Northwestern University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Christina Zelano, Assistant Professor, Northwestern University
ClinicalTrials.gov Identifier:
NCT04926961
Other Study ID Numbers:
  • STU00214694
First Posted:
Jun 15, 2021
Last Update Posted:
Jul 13, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Jul 13, 2022